UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000018949 |
|---|---|
| Receipt number | R000021922 |
| Scientific Title | Comparison of efficacy of anagliptin and alogliptin for lipid profile between type 2 diabetic patients |
| Date of disclosure of the study information | 2015/09/08 |
| Last modified on | 2017/09/10 23:35:46 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Comparison of efficacy of anagliptin and alogliptin for lipid profile between type 2 diabetic patients
Acronym
Comparison of efficacy of anagliptin and alogliptin for lipid profile
Scientific Title
Comparison of efficacy of anagliptin and alogliptin for lipid profile between type 2 diabetic patients
Scientific Title:Acronym
Comparison of efficacy of anagliptin and alogliptin for lipid profile
Region
| Japan |
Condition
Condition
type 2 diabetes mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
One of pleiotropic effect of DPP-4 inhibitors is for improving lipid profile.
This study aimed to compare the effectiveness of anagliptin and alogliptin for lipid profile in Type 2 diabetes.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
change of LDL-C at 24 weeks
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Cluster
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
anagliptin
subjects were allocated randomly by the envelope method to either of two treatment groups: anagliptin 200mg/day or alogliptin 25 mg/day(using DPP4 inhibitor was stopped). After 24-week oral administration of the allocated drug, we tested fasting blood samples.
Interventions/Control_2
alogliptin
alogliptin 25 mg/day(using DPP4 inhibitor was stopped). After 24-week oral administration of the allocated drug, we tested fasting blood samples.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Type 2 diabetes using DPP-4 inhibitors except for anagliptin and alogliptin, presented with LDL-C above 120mg/dl. Participants provided their informed consent to participate in the study.
Participants provided their informed consent to participate in the study.
Key exclusion criteria
Patients using glinide and insulin therapy, those who were or may have been pregnant, and those with severe renal dysfunction (s-Cre levels: male>1.4mg/dl, female>1.2mg/dl) were excluded.
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshiya Tanaka |
Organization
University of Occupational and Environmental Health
Division name
First Department of Internal Medicine, School of Medicine
Zip code
Address
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu
TEL
0936031611
tanaka@med.uoeh-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Akira Kurozumi |
Organization
University of Occupational and Environmental Health
Division name
First Department of Internal Medicine, School of Medicine
Zip code
Address
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu
TEL
0936031611
Homepage URL
akira@med.uoeh-u.ac.jp
Sponsor or person
Institute
University of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 09 | Month | 08 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2014 | Year | 03 | Month | 31 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 04 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 09 | Month | 30 | Day |
Date of closure to data entry
| 2015 | Year | 09 | Month | 30 | Day |
Date trial data considered complete
Date analysis concluded
| 2016 | Year | 04 | Month | 30 | Day |
Other
Other related information
Management information
Registered date
| 2015 | Year | 09 | Month | 08 | Day |
Last modified on
| 2017 | Year | 09 | Month | 10 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021922
